Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash & Equivalents (2021 - 2025)

Senti Biosciences has reported Cash & Equivalents over the past 5 years, most recently at $16.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 65.99% year-over-year to $16.4 million; the TTM value through Dec 2025 reached $16.4 million, down 65.99%, while the annual FY2025 figure was $16.4 million, 65.99% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $16.4 million at Senti Biosciences, up from $12.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $139.8 million in Q2 2022 and troughed at $10.5 million in Q3 2024.
  • A 5-year average of $46.8 million and a median of $36.8 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: soared 68.55% in 2022 and later plummeted 73.71% in 2023.
  • Year by year, Cash & Equivalents stood at $56.0 million in 2021, then rose by 2.83% to $57.6 million in 2022, then crashed by 37.7% to $35.9 million in 2023, then surged by 34.48% to $48.3 million in 2024, then tumbled by 65.99% to $16.4 million in 2025.
  • Business Quant data shows Cash & Equivalents for SNTI at $16.4 million in Q4 2025, $12.2 million in Q3 2025, and $21.6 million in Q2 2025.